PCSK9 and ovarian carcinoma: When the analysis was limited to the general population or BRCA1/2 mutation carriers, there was no significant association between genetically close NPC1L1 or PCSK9 inhibition or low-density lipoprotein cholesterol levels and epithelial ovarian cancer in the Mendelian randomized analysis of 22,406 women with invasive epithelial ovarian cancer and 40,941 control individuals (Yarmolinsky et al., 2020).